open access

Vol 68, No 1 (2017)
Original Paper
Published online: 2017-03-01
Submitted: 2015-11-05
Accepted: 2016-04-25
Get Citation

Thyroid lesions in patients with acromegaly — case-control study and update to the meta-analysis

Kosma Woliński, Adam Stangierski, Edyta Gurgul, Barbara Bromińska, Agata Czarnywojtek, Martha Lodyga, Marek Ruchała
DOI: 10.5603/EP.2017.0001
·
Pubmed: 28255974
·
Endokrynologia Polska 2017;68(1):2-6.

open access

Vol 68, No 1 (2017)
Original Paper
Published online: 2017-03-01
Submitted: 2015-11-05
Accepted: 2016-04-25

Abstract

Introduction: Acromegaly results from oversecretion of growth hormone and subsequently insulin growth factor-1. According to some authors, the disease can cause increased prevalence of nodular goitre and thyroid cancer (TC). However, the number of studies comparing acromegalic patients with control groups is low. We aimed to assess the prevalence of thyroid lesions in patients with acromegaly in comparison to an age- and sex-matched control group and to update the meta-analysis previously performed in our department by the same authors.

Material and methods: We searched medical documentation of patients with acromegaly treated in our department between 2003 and 2013. The prevalence of thyroid abnormalities was compared with the group of patients with hormonally inactive adrenal incidentalomas. To perform the meta-analytic part of the paper we also searched ten databases to find relevant papers.

Results: Two hundred and five patients with acromegaly and 184 patients with incidentalomas were included. Any thyroid lesions were present in 77.6% of patients with acromegaly vs. 63.0% with incidentalomas (p = 0.002), multinodular goitre — 66.8% vs. 47.8% (p = 0.0002), and TC- 5.4% vs. 2.7% (p = 0.21) respectively. For thyroid lesions the pooled odds ratio (OR) was 3.1 (95% confidence interval [CI] 1.8–5.5), and for TCs the OR was 4.5 (95% CI 1.9–10.3).

Conclusions: According to our results thyroid lesions were significantly more common in patients with acromegaly; in case of TC the difference was not significant. The updated meta-analysis showed significantly increased prevalence of both disorders. In conclusion, systematic thyroid examination should be an important part of follow-up in case of acromegalic patients. (Endokrynol Pol 2017; 68 (1): 2–6)

Abstract

Introduction: Acromegaly results from oversecretion of growth hormone and subsequently insulin growth factor-1. According to some authors, the disease can cause increased prevalence of nodular goitre and thyroid cancer (TC). However, the number of studies comparing acromegalic patients with control groups is low. We aimed to assess the prevalence of thyroid lesions in patients with acromegaly in comparison to an age- and sex-matched control group and to update the meta-analysis previously performed in our department by the same authors.

Material and methods: We searched medical documentation of patients with acromegaly treated in our department between 2003 and 2013. The prevalence of thyroid abnormalities was compared with the group of patients with hormonally inactive adrenal incidentalomas. To perform the meta-analytic part of the paper we also searched ten databases to find relevant papers.

Results: Two hundred and five patients with acromegaly and 184 patients with incidentalomas were included. Any thyroid lesions were present in 77.6% of patients with acromegaly vs. 63.0% with incidentalomas (p = 0.002), multinodular goitre — 66.8% vs. 47.8% (p = 0.0002), and TC- 5.4% vs. 2.7% (p = 0.21) respectively. For thyroid lesions the pooled odds ratio (OR) was 3.1 (95% confidence interval [CI] 1.8–5.5), and for TCs the OR was 4.5 (95% CI 1.9–10.3).

Conclusions: According to our results thyroid lesions were significantly more common in patients with acromegaly; in case of TC the difference was not significant. The updated meta-analysis showed significantly increased prevalence of both disorders. In conclusion, systematic thyroid examination should be an important part of follow-up in case of acromegalic patients. (Endokrynol Pol 2017; 68 (1): 2–6)

Get Citation

Keywords

thyroid; thyroid cancer; acromegaly; meta-analysis; pituitary;

About this article
Title

Thyroid lesions in patients with acromegaly — case-control study and update to the meta-analysis

Journal

Endokrynologia Polska

Issue

Vol 68, No 1 (2017)

Pages

2-6

Published online

2017-03-01

DOI

10.5603/EP.2017.0001

Pubmed

28255974

Bibliographic record

Endokrynologia Polska 2017;68(1):2-6.

Keywords

thyroid
thyroid cancer
acromegaly
meta-analysis
pituitary

Authors

Kosma Woliński
Adam Stangierski
Edyta Gurgul
Barbara Bromińska
Agata Czarnywojtek
Martha Lodyga
Marek Ruchała

References (17)
  1. Ruchała M, Szczepanek-Parulska E, Komorowska-Piotrowiak E. Diagnostyka i leczenie akromegalii. Oncoreview. 2011; 4: 240–247.
  2. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25(1): 102–152.
  3. Ruchała M, Szczepanek-Parulska E, Fularz M, et al. Risk of neoplasms in acromegaly. Contemp Oncol (Pozn). 2012; 16(2): 111–117.
  4. Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review. PLoS One. 2014; 9(2): e88787.
  5. Gullu BE, Celik O, Gazioglu N, et al. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 2010; 13(3): 242–248.
  6. Balkany C, Cushing GW. An association between acromegaly and thyroid carcinoma. Thyroid. 1995; 5(1): 47–50.
  7. Dąbrowska AM, Tarach JS, Kurowska M, et al. Thyroid diseases in patients with acromegaly. Arch Med Sci. 2014; 10(4): 837–845.
  8. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998; 83(8): 2730–2734.
  9. Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002; 13(5): 395–400.
  10. Ruchala M, Skiba A, Gurgul E, et al. The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol Lett. 2009; 30(3): 382–386.
  11. Reverter JL, Fajardo C, Resmini E, et al. Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS One. 2014; 9(8): e104174.
  12. Gasperi M, Martino E, Manetti L, et al. Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002; 25(3): 240–245.
  13. Gembicki M, Ruchała M, Bartkowiak M, et al. The results of epidemiological studies concerning iodine deficiency and goiter in Poznań Region (Poznań coordinating center). Endokrynol Pol. 1993; 44(3): 317–332.
  14. Szybiński Z. Polish Council for Control of Iodine Deficiency Disorders. Work of the Polish Council for Control of Iodine Deficiency Disorders, and the model of iodine prophylaxis in Poland. Endokrynol Pol. 2012; 63(2): 156–160.
  15. Bałdys-Waligórska A, Krzentowska A, Gołkowski F, et al. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 2010; 61(1): 29–34.
  16. Herrmann BL, Baumann H, Janssen OE, et al. Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes. 2004; 112(5): 225–230.
  17. Popovic V, Damjanovic S, Micic D, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998; 49(4): 441–445.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl